-
Product Insights
NewDual Specificity Protein Kinase TTK – Drugs In Development, 2024
The Dual Specificity Protein Kinase TTK pipeline drugs market research report outlays comprehensive information on the Dual Specificity Protein Kinase TTK targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Undisclosed, and Central Nervous System which include indications of Triple-Negative Breast Cancer (TNBC), Solid Tumor, Autoimmune Disorders, Unspecified, and Neuroinflammation. It also reviews key players involved...
-
Product Insights
NewDual Specificity Protein Kinase CLK2 – Drugs In Development, 2024
The Dual Specificity Protein Kinase CLK2 pipeline drugs market research report outlays comprehensive information on the Dual Specificity Protein Kinase CLK2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Musculoskeletal Disorders which include indications of Solid Tumor, Endometrial Cancer, and Osteoarthritis. It also reviews key players involved in Dual Specificity Protein Kinase CLK2 targeted therapeutics...
-
Product Insights
NewDual Specificity Tyrosine Phosphorylation Regulated Kinase 1B – Drugs In Development, 2024
The Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B pipeline drugs market research report outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Dermatology, and Non Malignant Disorders which include indications of Colorectal Cancer, Non-Small Cell Lung Cancer, Obesity, Cellulite, Benign Tumor, and Adiposis...
-
Product Insights
NewDual Specificity Tyrosine Phosphorylation Regulated Kinase 1A – Drugs In Development, 2024
The Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A pipeline drugs market research report outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Oncology, Genetic Disorders, and Metabolic Disorders which include indications of Alzheimer's Disease, Dementia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Down...
-
Product Insights
NewDual Specificity Mitogen Activated Protein Kinase Kinase 1 – Drugs In Development, 2024
The Dual Specificity Mitogen Activated Protein Kinase Kinase 1 pipeline drugs market research report outlays comprehensive information on the Dual Specificity Mitogen Activated Protein Kinase Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Central Nervous System which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Neurofibromatoses Type...
-
Product Insights
NewDual Specificity Mitogen Activated Protein Kinase Kinase 2 – Drugs In Development, 2024
The Dual Specificity Mitogen Activated Protein Kinase Kinase 2 pipeline drugs market research report outlays comprehensive information on the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Central Nervous System which include indications of Solid Tumor, Low-Grade Glioma, Neurofibromatoses Type I (Von...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XO/URAT1 Dual Inhibitor in Hyperuricemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XO/URAT1 Dual Inhibitor in Hyperuricemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XO/URAT1 Dual Inhibitor in Hyperuricemia Drug Details: The drug candidate...
-
Product Insights
NewPhosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN – Drugs In Development, 2024
The Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN pipeline drugs market research report outlays comprehensive information on the Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Oncology, Women's Health, and Toxicology which include indications of Acute Spinal Cord Injury,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutikizumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutikizumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutikizumab in Ulcerative Colitis Drug Details: Lutikizumab is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutikizumab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutikizumab in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutikizumab in Hidradenitis Suppurativa Drug Details: Lutikizumab is under development for...